The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis

Table 1 Summary of hazard ratios (HR) for cardiorenal outcomes in study populations with heart failure, chronic kidney disease, or type 2 diabetes

Participant Groups		T2D	Class	MACE	All-cause mortality	CV death	Non-fatal MI	Non-fatal Stroke	HHF	CV Death or HHF	Kidney composite^¥
HF	EF ≤ 40%*	+/-	SGLT2i	NA	0.84 (0.72, 0.97)	0.84 (0.71, 0.98)	NA	NA	0.69 (0.64, 0.75)	0.75 (0.69, 0.81)	0.59 (0.42, 0.83)
HF	EF > 40%	+/-	SGLT2i	NA	0.97 (0.89, 1.06)	0.96 (0.82, 1.14)	NA	NA	0.74 (0.67, 0.82)	0.79 (0.73, 0.86)	1.00 (0.82, 1.23)
CKD	Any EF	+/-	SGLT2i	0.85 (0.78, 0.92)	0.82 (0.75, 0.90)	0.85 (0.78, 0.93)	0.77 (0.62, 0.95)	0.78 (0.49, 1.25)	0.65 (0.59, 0.72)	0.75 (0.70, 0.79)	0.68 (0.60, 0.76)
CKD	Any EF	+/-	GLP1-RA	0.87 (0.75, 1.003)	0.86 (0.72, 1.02)	0.86 (0.63, 1.16)	0.86 (0.70, 1.06)	0.84 (0.51, 1.40)	0.91 (0.73, 1.15)	NA	0.85 (0.78, 0.92)
T2D with ASCVD or multiple risk factors	Any EF or eGFR	+	SGLT2i	0.88 (0.82, 0.93)	0.87 (0.81, 0.94)	0.86 (0.80, 0.93)	0.90 (0.83, 0.98)	0.99 (0.88, 1.11)	0.70 (0.65, 0.75)	0.77 (0.73, 0.80)	0.67 (0.59, 0.75)
T2D with ASCVD or multiple risk factors	Any EF or eGFR	+	GLP1-RA	0.86 (0.80, 0.93)	0.88 (0.82, 0.94)	0.87 (0.80, 0.94)	0.94 (0.88, 1.02)	0.84 (0.76, 0.94)	0.91 (0.83, 1.002)	0.89 (0.81, 0.98)	0.78 (0.70, 0.87)

ASCVD: atherosclerotic cardiovascular disease; CKD: chronic kidney disease; CV: cardiovascular; eGFR: estimated glomerular filtration rate; GLP-1RA: glucagon-like peptide-1 receptor agonists; HHF: hospitalization for heart failure; EF: ejection fraction; MACE: major adverse cardiac events; MI: myocardial infarction; NA: not applicable; SGLT2i, sodium-glucose co-transporter 2 inhibitors; T2D, type 2 diabetes; +/-, with/without. Light green indicates a significant HR and dark green indicates a significant HR that is statistically different than in the comparator group, namely participants with EF ≤ 40% versus > 40% in SGLT2i trials of participants with HF and SGLT2i versus GLP1-RA in participants with T2D with ASCVD or multiple risk factors
*DECLARE and VERTIS CV reported results using LVEF < 45% and LVEF ≥ 45.
^¥ Renal death, progression to ESKD or reduced eGFR.

ISSN: 1475-2840